CRIS
Curis, Inc.
A clinical-stage biotechnology company in Lexington, Massachusetts, developing emavusertib, an oral pill for blood cancers like primary central nervous system lymphoma and chronic lymphocytic leukemia. Formed in 2000 from the merger of three Boston-area biotech firms, its logo carries a musical fermata—a symbol that holds a note—reflecting its goal of prolonging life and curing cancer. Curis also helped develop Erivedge, an approved treatment for advanced basal cell carcinoma.
CUSIP: 231269101HealthcareUS1 holder
Total Value
$16.27M
Total Shares
24.90M
Net Share Change
-2.85M
Activity
1 selling
Investor
Value
Shares
Weight
Change
